Array BioPharma Issues Update on ARRY-520 for Multiple Myeloma at '13 ASHM

Array BioPharma Inc. (NASDAQ: ARRY ) announced positive data for newly named filanesib (ARRY-520) as a single agent and in combination with proteasome inhibitors (PI) in patients with multiple myeloma (MM) at the 2013 Annual Meeting of the American Society of Hematology. Filanesib is a highly selective, targeted KSP inhibitor with a mechanism